Milestone Pharmaceuticals Inc.

Ladies and gentlemen, good morning and welcome to the Milestone Pharma first quarter 2026 earnings conference call. At this time, all participants are in listen-only mode. A brief question and answer session will follow the formal presentation. If anyone requires operator assistance during the conference, please signal the operator by pressing star and zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Michael Wood of LifeSci Advisors. Please go ahead.

Thank you, operator. Good morning, everyone, and welcome to the Milestone Pharmaceuticals first quarter 2026 financial results and business update conference call. Earlier this morning, the company issued a press release providing an overview of its financial results for the quarter ended March 31, 2026 and recent corporate highlights. The release can be accessed on the investors and meters section of the company's website, milestonepharma.com. Before we begin, I'd like to remind you that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause actual clinical programs, future results, progress, timing, performances, or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties associated with milestones, business, and factors that could cause or contribute to such differences are described in detail in the company's filings with the SEC, including in the risk factors section of the annual report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 20, 2026. Speaking on the call today will be Joseph Oliveto, President and Chief Executive Officer of Milestone, Lorenz Muller, Chief Commercial Officer, and Amit Hasija, Chief Financial Officer and EVP of Corporate Development. In addition, Dr. David Borussia, the company's Chief Medical Officer, will also be available on the call during the Q&A session. So with that, I'll turn the call over to Joseph Oliveto. Joe, please go ahead.

Thank you, Michael. Good morning, everyone, and thank you for joining us today. This is an exciting day as it represents our first analyst call reporting on our first ever quarter, or more accurately, partial quarter, of sales since the commercial launch of Cardamis for acute episodes of paroxysmal supraventricular tachycardia, or PSVT. Today, our prepared remarks will highlight three advances or updates since our last quarterly call. First, we'll provide our thoughts on the launch of Cardamist. Second, we'll discuss the initiation of our phase three pivotal trial for Atripamil for patients with atrial fibrillation and rapid ventricular rate, or AFib-RVR. And lastly, we'll provide an update on our financials from our CFO, Hasidja. Let's start with the launch. To recap, Cardamist, the brand name for Atripamil, was approved by the FDA on December 12th as the first and only rapid-acting, self-administered prescription therapy for acute PSVT episodes in adults. Following approval, we immediately mobilized our launch plan. We quickly engaged our distribution channels such that Cardamist became readily available through retail pharmacies by the end of January. We then began promotion of Cardamist in earnest in mid-February including the deployment of our national sales force of approximately 60 sales representatives. Launching within two months of the approval was an aggressive goal that we successfully met in Q1. Now, a little less than three months since the launch, we're excited to share the emerging themes we've observed so far. Cardiology healthcare providers across the board, including physicians, nurses, nurse practitioners, and physician's assistants are consistently responding positively to Cardamist. It seems clear to us that the HCP audience we've engaged so far quickly understands the value that Cardamist brings to the patients with SVT due to its safety profile and ease of effective self-administration. Insurers continue to collaborate with us on pathways to coverage. with the goal of adding cardamom to their formularies. A great example of this is our earliest major win, Express Scripts national formulary coverage. Express Scripts is one of the three major pharmacy benefit managers, or PBMs, which, when combined with the other two major PBMs, account for more than 80% of commercially covered lives in the United States. Perhaps most gratifying for us is the positive initial feedback we are receiving from the patient community, and specifically those patients who've received Cardamist. We gain these insights of patient experiences through our ongoing patient engagement activities, our social media monitoring, and through physicians and nurses' feedback, much of which is in the form of unsolicited texts, calls, and emails. The stories take the form of two flavors, the first being those patients who've used Cardamist and have had a positive experience during an event, but also, interestingly, stories from some patients who relay excitement simply from having obtained cardamom from their pharmacy and not even having used it yet. These patients describe having an increased sense of preparedness and security for when their next event will occur. All of these patient stories are very valuable reminder of why we do what we do. So I'll hand it over to Lorenz to provide some additional details on the launch.